A new trading day began on Friday, with Avidity Biosciences Inc (NASDAQ: RNA) stock price down -0.75% from the previous day of trading, before settling in for the closing price of $30.81. RNA’s price has ranged from $21.51 to $56.00 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 49.32% over the past five years. Meanwhile, its annual earnings per share averaged -36.98%. With a float of $109.84 million, this company’s outstanding shares have now reached $120.51 million.
Let’s look at the performance matrix of the company that is accounted for 391 employees. In terms of profitability, gross margin is 66.42%, operating margin of -4853.44%, and the pretax margin is -4136.0%.
Avidity Biosciences Inc (RNA) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Avidity Biosciences Inc is 8.88%, while institutional ownership is 107.71%. The most recent insider transaction that took place on May 01 ’25, was worth 190,324. In this transaction Chief Program Officer of this company sold 5,875 shares at a rate of $32.40, taking the stock ownership to the 50,554 shares. Before that another transaction happened on May 01 ’25, when Company’s Officer proposed sale 5,875 for $32.65, making the entire transaction worth $191,819.
Avidity Biosciences Inc (RNA) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -36.98% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.71% during the next five years compared to -34.37% drop over the previous five years of trading.
Avidity Biosciences Inc (NASDAQ: RNA) Trading Performance Indicators
Here are Avidity Biosciences Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 16.91. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 412.77.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.01, a number that is poised to hit -0.95 in the next quarter and is forecasted to reach -4.42 in one year’s time.
Technical Analysis of Avidity Biosciences Inc (RNA)
Avidity Biosciences Inc (NASDAQ: RNA) saw its 5-day average volume 1.0 million, a negative change from its year-to-date volume of 1.45 million. As of the previous 9 days, the stock’s Stochastic %D was 73.30%. Additionally, its Average True Range was 2.10.
During the past 100 days, Avidity Biosciences Inc’s (RNA) raw stochastic average was set at 61.00%, which indicates a significant decrease from 77.54% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.53% in the past 14 days, which was higher than the 72.01% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $29.49, while its 200-day Moving Average is $36.41. Nevertheless, the first resistance level for the watch stands at $30.95 in the near term. At $31.31, the stock is likely to face the second major resistance level. The third major resistance level sits at $31.86. If the price goes on to break the first support level at $30.04, it is likely to go to the next support level at $29.49. Assuming the price breaks the second support level, the third support level stands at $29.13.
Avidity Biosciences Inc (NASDAQ: RNA) Key Stats
With a market capitalization of 3.69 billion, the company has a total of 120,520K Shares Outstanding. Currently, annual sales are 10,900 K while annual income is -322,300 K. The company’s previous quarter sales were 1,570 K while its latest quarter income was -115,770 K.
